| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font
First page > Show document

Show document Help

Title:Intenzivnejše neoadjuvantno zdravljenje lokalno napredovalnega raka danke
Authors:ID Golo, Danijela (Author)
ID Velenik, Vaneja (Mentor) More about this mentor... New window
ID Potrč, Stojan (Comentor)
Files:.pdf DOK_Golo_Danijela_2018.pdf (1,41 MB)
MD5: 6DDBAF6283A43A7D9340251A878518BC
PID: 20.500.12556/dkum/a1fb5468-4ce0-4602-a7f1-3be7f337022c
 
Language:Slovenian
Work type:Doctoral dissertation
Organization:MF - Faculty of Medicine
Abstract:Izhodišče in namen Z namenom izboljšanja učinkovitosti zdravljenja lokalno napredovalega raka danke (LNRD) smo okrepili neoadjuvantni del z umestitvijo treh krogov sicer adjuvantne kemoterapije kot en indukcijski in dva konsolidacijska kroga. Materiali in metode Med oktobrom 2011 in aprilom 2013 je bilo v raziskavi zdravljenih 66 bolnikov z LNRD z uvodnim krogom, kemoradioterapijo in dvema konsolidacijskima krogoma kemoterapije. Operacija je sledila po 2 tednih, nato so bolniki prejeli še 3 kroge adjuvantne kemoterapije. Obsevani so bili na linearnem pospeševalniku, s tumorsko dozo 45 Gy ter dodatkom doze do 50,4 Gy na T2-3 in do 54 Gy na T4 tumor, v dnevnih odmerkih po 1,8 Gy. Sočasno so prejemali kapecitabin v odmerku 825 mg/m² dvakrat dnevno, vključno z vikendi. Uvodno, konsolidacijsko in pooperativno so prejemali kapecitabin v odmerku 1250 mg/m²/12 ur v 14-ih zaporednih dneh s tedenskim razmikom med krogi. Primarni cilj je bil popolni patološki odgovor (pCR). Rezultati Triinštirideset (65.1%) bolnikov je prejelo zdravljenje po protokolu. Skladnost z indukcijsko, konsolidacijsko in adjuvantno kemoterapijo je bila 98,5 %, 92 % in 87,3 %. Radiokemoterapijo je zaključilo 65/66 bolnikov z 13,6 % G ≥ 3 ne-hematološko toksičnostjo. Stopnja pCR (17,5 %) sicer ni bila statistično značilno boljša, opazovali pa smo precejšnje znižanje N (77,7 %) in celokupnega stadija (79,3 %). V srednjem času sledenja 55 mesecev smo zabeležili en lokalni recidiv (LR = 1,6 %), 64,0 % (95 % IZ 63,89 – 64,11) 5 letno preživetje brez bolezni (PBB) in 69,5 % (95 % IZ 69,39 – 69,61) 5 letno celokupno preživetje (CP). Zaključki Okrepitev predoperativnega zdravljenja LNRD z dodatno kemoterapijo s kapecitabinom pred in po kemoradioterapiji spremlja sprejemljiva toksičnost, zato jo bolniki dobro prenašajo in jih večina tudi zaključi zdravljenje po protokolu. Z njim sicer ne izboljšamo lokalnega učinka, dosegamo pa dobro lokalno kontrolo, PBB in CP.
Keywords:rak danke, neoadjuvantna kemoterapija, predoperativna kemoradioterapija, popolni patološki odgovor, popolna neoadjuvantna terapija
Place of publishing:Maribor
Year of publishing:2018
PID:20.500.12556/DKUM-69738 New window
COBISS.SI-ID:297815552 New window
NUK URN:URN:SI:UM:DK:WZO9MHZF
Publication date in DKUM:18.12.2018
Views:2387
Downloads:131
Metadata:XML DC-XML DC-RDF
Categories:MF
:
GOLO, Danijela, 2018, Intenzivnejše neoadjuvantno zdravljenje lokalno napredovalnega raka danke [online]. Doctoral dissertation. Maribor. [Accessed 18 April 2025]. Retrieved from: https://dk.um.si/IzpisGradiva.php?lang=eng&id=69738
Copy citation
  
Average score:
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:20.02.2018

Secondary language

Language:English
Title:Intensified neoadjuvant treatment of locally advanced rectal cancer
Abstract:Background and Purpose To improve the treatment efficacy for locally advanced rectal cancer (LARC) by shifting half of adjuvant chemotherapy (ChT) preoperatively to one induction and two consolidation cycles. Materials and Methods Between October 2011 and April 2013, 66 patients with LARC were treated with one induction chemotherapy cycle followed by chemoradiotherapy (CRT) and two consolidation cycles. After two weeks, the patients were operated and administered three adjuvant capecitabine cycles. Patients were irradiated with a linear accelerator, using a 1.8 Gy daily fraction to 45.0 Gy with a sequential boost to 5.4 Gy in T2-3, and to 9.0 Gy in T4 tumors. The dose of concomitant capecitabine was 825 mg/m²/12h and the dose of neo/adjuvant capecitabine 1250 mg/m²/12h in 14 consecutive days. The primary endpoint was pathologic complete response (pCR). Results 43 (65.1 %) patients were treated according to protocol. The compliance rates for induction, consolidation, and adjuvant ChT were 98.5 %, 92 % and 87.3 %, respectively. CRT was completed by 65/66 patients, with G ≥ 3 non-hematologic toxicity at 13.6 %. The rate of pCR (17.5 %) was not increased, but N and the total-down staging rates were 77.7 % and 79.3 %, respectively. In a median follow-up of 55 months, we recorded one local relapse (LR = 1.6 %). The 5-year disease-free survival and overall survival rates were 64.0 % (95 % CI 63.89 – 64.11) and 69.5 % (95 % CI 69.39 – 69.61), respectively. Conclusions In LARC, the intensification of preoperative treatment by means of capecitabine before and after radiotherapy is well tolerated, with a high compliance rate and acceptable toxicity. Though it does not improve the local effect, it achieves a high LR rate, DFS, and OS.
Keywords:rectal cancer, neoadjuvant chemotherapy, preoperative chemoradiotherapy, pathologic complete response, total neoadjuvant therapy


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica